I must admit to being surprised at not seeing any top-line data points relating to Dr.BP's assays:

Quote:

---

Other Outcome Measures:
1. Change in size of lesion area by chest radiograph or CT [ Time Frame: Day 14 ]
2. Change from baseline in serum cytokine and chemokine levels [ Time Frame: Days 3, 7, and 14 ]
3. Change from baseline in CCR5 receptor occupancy levels for Tregs and macrophages [ Time Frame: Days 3, 7, and 14 ]
4. Change from baseline in CD3+, CD4+ and CD8+ T cell count [ Time Frame: Days 3, 7, and 14 ]

---

And also, viral load which I hope has been measured for both M/M and S/C trials.

But I guess those are not being included in the this summary.

I do hope they help to tell the story of leronlimab's MOA.

I really hope Dr.BP's peer reviewed manuscript can be published soon.